← All trials
NCT04588311
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 9, 2020
- Primary completion
- Mar 31, 2025
- Completion date
- Mar 31, 2025
- First posted
- Oct 19, 2020
- Last posted
- Nov 12, 2020
- Enrollment
- 2500
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Monash UniversityLead sponsor
- National University of IrelandCollaborator
- Health Research Board, IrelandCollaborator
- Monash UniversityCollaborator
- Health Research Council, New ZealandCollaborator
- Medical Research Future Fund (MRFF)Collaborator
- ANZICS Clinical Trials GroupCollaborator
- Western HealthStudy chair
- University College DublinStudy chair
- Irish Critical Care Clinical Trials NetworkCollaborator
- Medical Research Institute of New ZealandCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.